Global Canine Stem Cell Therapy Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Canine Stem Cell Therapy Market Research Report 2024
Animal stem cell therapy is a usage of animal’s stem cell to treat a disease or disorder. The ability of stem cell is to divide and differentiate into a cell with specialized function useful for repairing body tissues damaged by injury or disease. The animal stem cell therapy process involves three steps which include collection of stem cell sample from animals and preparing the sample to concentrate the stem cells. Finally, the therapy includes transferring the stem cells into the injured site for treatment. Animal stem cell therapy increases the expectancy of life in animals with no side effects. It is available for the treatment of arthritis, degenerative joint disorders, tendon, and ligaments injuries in animals. Stem cell therapy is most often used to treat dogs, cats, and horses. But recent developments made it possible to use animal stem cell therapy in tiger, pig, etc. Present animal stem cell therapy is studied in treatments of the inflammatory bowel, kidney, liver, heart and immune-mediated diseases respectively.
According to MRAResearch’s new survey, global Canine Stem Cell Therapy market is projected to reach US$ 79 million in 2033, increasing from US$ 61 million in 2022, with the CAGR of 3.7% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Canine Stem Cell Therapy market research.
Market competition is intense. Medivet Biologics LLC, VETSTEM BIOPHARMA and J-ARM, etc. are the leaders of the industry, with about 52% market shares.
North America is the largest consumption region of animal stem cell therapy, with a consumption market share nearly 58%. Japan is the second largest supplier of animal stem cell therapy, enjoying production market share nearly 15%.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Canine Stem Cell Therapy market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
VETSTEM BIOPHARMA
Cell Therapy Sciences
Regeneus
Aratana Therapeutics
Medivet Biologics
Okyanos
Vetbiologics
VetMatrix
Magellan Stem Cells
ANIMAL CELL THERAPIES
Stemcellvet
Segment by Type
Allogeneic Stem Cells
Autologous Stem cells
Veterinary Hospitals
Veterinary Clinics
Veterinary Research Institutes
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Canine Stem Cell Therapy report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to MRAResearch’s new survey, global Canine Stem Cell Therapy market is projected to reach US$ 79 million in 2033, increasing from US$ 61 million in 2022, with the CAGR of 3.7% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Canine Stem Cell Therapy market research.
Market competition is intense. Medivet Biologics LLC, VETSTEM BIOPHARMA and J-ARM, etc. are the leaders of the industry, with about 52% market shares.
North America is the largest consumption region of animal stem cell therapy, with a consumption market share nearly 58%. Japan is the second largest supplier of animal stem cell therapy, enjoying production market share nearly 15%.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Canine Stem Cell Therapy market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
VETSTEM BIOPHARMA
Cell Therapy Sciences
Regeneus
Aratana Therapeutics
Medivet Biologics
Okyanos
Vetbiologics
VetMatrix
Magellan Stem Cells
ANIMAL CELL THERAPIES
Stemcellvet
Segment by Type
Allogeneic Stem Cells
Autologous Stem cells
Segment by Application
Veterinary Hospitals
Veterinary Clinics
Veterinary Research Institutes
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Canine Stem Cell Therapy report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source